Article

B&L to join with German-based refractive surgery business

B&L to join with German-based refractive surgery business

Rochester, NY-Bausch & Lomb (B&L) is joining a German laser surgery equipment developer to create a new refractive surgery business.

"We believe that our investment of assets in the joint venture will help advance the refractive industry, benefiting ophthalmologists and patients worldwide," said Gerald M. Ostrov, chairman and chief executive officer, B&L. "20/10 Perfect Vision's development of presbyopia-correcting treatments using its Femtec femtosecond laser-when paired with our proven refractive products, R&D insights, and global sales and marketing resources-holds tremendous potential to stimulate growth in corneal refractive surgery."

"We are excited about this unique opportunity to form a global company committed to focusing on refractive laser surgery," said Dr. Kristian Hohla, executive president of 20/10 Perfect Vision. "Combining innovative teams, visionary technologies, and state-of-the-art refractive surgery products will yield a powerful portfolio of options for customers and patients."

B&L will have a large investment stake in the venture, which will include 20/10 Perfect Vision AG's technology and B&L refractive surgery products and sales and marketing operations.

The new company, which has not yet been named, will be based in Germany including about 20 of B&L's 1,600 local workers. The new joint venture is scheduled to be complete by the end of the year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.